Cullinan Oncology Inc. (CGEM): Price and Financial Metrics
GET POWR RATINGS... FREE!
CGEM Stock Price Chart Interactive Chart >
CGEM Price/Volume Stats
| Current price | $11.47 | 52-week high | $15.89 |
| Prev. close | $11.15 | 52-week low | $7.30 |
| Day low | $11.07 | Volume | 114,100 |
| Day high | $11.58 | Avg. volume | 134,944 |
| 50-day MA | $11.36 | Dividend yield | N/A |
| 200-day MA | $12.21 | Market Cap | 523.17M |
Cullinan Oncology Inc. (CGEM) Company Bio
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Latest CGEM News From Around the Web
Below are the latest news stories about CULLINAN ONCOLOGY INC that investors may wish to consider to help them evaluate CGEM as an investment opportunity.
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin LymphomaCAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-978, a CD19/CD3 T-cell engaging antibody construct with a human serum albumin (HSA) binding domain to increase serum half-life. Cullinan Oncology will initially evaluate CLN-978 in a Phase 1 tria |
12 Most Undervalued Pharma Stocks To Buy According To Hedge FundsIn this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has assigned a ‘Neutral’ outlook to the global pharmaceutical and biotech sector, indicating Fitch’s […] |
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 37,000 shares of its common stock to three employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan. The stock options were granted |
11 Cheap Value Stocks to Buy According to Seth KlarmanIn this article, we discuss the 11 cheap value stocks to buy according to Seth Klarman. If you want to read about some more stocks in the Klarman portfolio, go directly to 5 Cheap Value Stocks to Buy According to Seth Klarman. Value investors like Seth Klarman of Boston-based Baupost Group have come under increased […] |
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsInitiated pivotal study for zipalertinib (CLN-081/TAS6417) Increased ownership in MICA subsidiary, which holds worldwide rights to CLN-619, from 54% to 92% Continued enrollment in CLN-049 and CLN-619 clinical studies with initial clinical data updates on track for mid-2023 Cash and investments of approximately $607 million as of September 30, 2022 CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) a biopharmaceutical company focused on modality-agnostic ta |
CGEM Price Returns
| 1-mo | 10.08% |
| 3-mo | -15.79% |
| 6-mo | -13.76% |
| 1-year | -10.67% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 8.72% |
| 2022 | -31.63% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...